Skip to main content

Table 1 Clinical characteristics of patient groups

From: Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy

  Ovarian cancer group (n = 225) Breast and ovarian cancer group (n = 64)
Mean age at ovarian cancer diagnosis in years (range) 48.8 (16.9-70.6) 51.2 (33.8-66.9)
Mean age at breast cancer diagnosis in years (range)   48.1 (25.0-72.9)
BRCA1 mutation status   
• Negative 198 (88.0%) 46 (71.9%)
• Positive 27 (12.0%) 18 (28.1%)
BRCA1 mutation type   
• 5382insC (c.5266dupC) 17 (63.0%) 14 (77.8%)
• 300 T/G (c.181 T > G) 8 (29.6%) 2 (11.1%)
• 185delAG (c.68-69delAG) 2 (7.4%) 2 (11.1%)
• 4153delA (c. 4034delA) -- --
• 3819del5 (c.3700_3704del5) -- --
Ovarian Cancer
FIGO   
• I 73 (32.4%) 16 (25.0%)
• II 33 (14.7%) 5 (7.8%)
• III 95 (42.2%) 31 (48.5%)
• IV 13 (5.8%) 2 (3.1%)
• Unspecified/unknown 11 (4.9%) 10 (15.6%)
GRADE   
• G1- well differentiated 34 (15.1%) 3 (4.7%)
• G2- moderately differentiated 98 (43.6%) 20 (31.2%)
• G3- undifferentiated 86 (38.2%) 29 (45.3%)
• G4 1 (0.4%) --
• unspecified/unknown 6 (2.7) 12 (18.8%)
Histology   
• Serous 121 (53.8%) 41 (64.1%)
• Mucinous 23 (10.2%) 2 (3.1%)
• Endometrioid 33 (14.7%) 2 (3.1%)
• Clear cell 6 (2.7%) 1 (1.6%)
• Other/unspecified 41 (18.2%) 15 (23.4%)
• Unknown 1 (0.4%) 3 (4.7%)
Breast Cancer
GRADE   
• G1- well differentiated   10 (15.6%)
• G2- moderately differentiated   22 (34.4%)
• G3- undifferentiated   6 (9.4%)
• Unspecified/unknown   26 (40.6%)
Histology   
• Ductal carcinoma in situ   1 (1.6%)
• Ductal carcinoma   44 (68.7%)
• Lobular carcinoma   1 (1.6%)
• Medullary carcinoma   3 (4.7%)
• Other   13 (20.3%)
• Unspecified   2 (3.1%)